BioSpace News Archive

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that it will host an investor event on updated data from the ongoing MARIO-3 clinical study during the San Antonio Breast Cancer Symposium.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting a closed satellite event on December 9, 2021 at SABCS in San Antonio, Texas.

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that scientists associated with the Company have published a review article entitled “GABAkines-Advances in the discovery, development, and commercialization of positive allosteric modulators of GAVA receptors.”

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), today announced that Rupert D’Souza, Ph.D., M.B.A., has joined Adverum as the company’s chief financial officer (CFO).

Emergen Research has published its latest report titled “Culture Media Market, By Type, By Research Type, By Application, By End-use, and By Region Forecast to 2028”

According to Emergen Research, the global Fc fusion protein market size was USD 26.97 billion in 2020 and is expected to reach USD 59.48 billion in 2028 and register a revenue CAGR of 10.5% during the forecast period, 2021-2028.

Sino Biological’s new Omicron product line includes recombinant Omicron Spike proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognizing the Omicron Spike protein, and the Omicron pseudovirus assay CRO service.

According to Emergen Research, the global wireless brain sensor market size was USD 391.7 million in 2020 and is expected to reach USD 804.3 million in 2028 and register a revenue CAGR of 9.5% during the forecast period, 2021-2028.

Satellos welcomes new board members to strengthen its pharmaceutical and North American capital markets expertise in support of its value-build strategy.

Halberd Corporation (OTC PINK: HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF).